News articles about Apellis Pharmaceuticals (NASDAQ:APLS) have been trending somewhat negative recently, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Apellis Pharmaceuticals earned a media sentiment score of -0.03 on Accern’s scale. Accern also gave press coverage about the company an impact score of 47.8186633932873 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
A number of equities research analysts have weighed in on the stock. ValuEngine raised shares of Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. B. Riley downgraded shares of Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $27.00 price target for the company. in a report on Thursday, April 12th. Zacks Investment Research downgraded shares of Apellis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, May 3rd. Finally, JPMorgan Chase upped their price target on shares of Apellis Pharmaceuticals from $31.00 to $35.00 and gave the company an “overweight” rating in a report on Friday, March 23rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $27.50.
APLS stock opened at $23.91 on Wednesday. The company has a quick ratio of 22.37, a current ratio of 22.37 and a debt-to-equity ratio of 0.21. Apellis Pharmaceuticals has a one year low of $23.66 and a one year high of $24.26. The stock has a market cap of $1.38 billion and a price-to-earnings ratio of -6.51.
Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Monday, April 30th. The company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.11). sell-side analysts predict that Apellis Pharmaceuticals will post -1.53 EPS for the current year.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology.
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.